Komori
ASKA Pharmaceutical Holdings (4886) · RiskFirst statedLatest Governance (2026-10-01): "Advanced"

Identifying Nature-Related Risks and Opportunities Under TNFD

First written in FY2026. 1 of 2 entries say "Advanced", first in 2026-10-01. Latest entry: 2026-10-01.

2entries
1years
1from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY20262026: 22026
Same theme, other companies
Assessment of Nature-Related Risks and Opportunities Using TNFD and LEAPA theme 70 companies write about · 4 as a headwind · 55 as a tailwind

38 other companies' latest entry also says "Advanced".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 70 companies compared. The sentences above are computed from all 70.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
ASKA Pharmaceutical Holdings's next results are scheduled for 2026-11-04. Read the earnings preview It last moved in the Governance of 2026-10-01: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Identifying Nature-Related Risks and Opportunities Under TNFD | ASKA Pharmaceutical Holdings Co.,Ltd. (4886) | Komori